Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fed Conditions

NCT01052792 | Completed Phase 1

• 1 other identifier: CR-BE-138-NAPR-2005
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

An open label randomised, two-treatment,two-period, two-sequence, single-dose, crossover, comparative bioequivalence study.

Conditions

Healthy

Keywords

Bioequivalence; Naproxen; crossover

Outcome Measures

Primary Outcomes (1)

• Bioequivalence based on Cmax and AUC parameters

  3 months

Study Arms (2)

Naproxen Sodium 550 mg Tablets

EXPERIMENTAL

Naproxen Sodium 550 mg Tablets of Dr. Reddy's Laboratories Limited

Drug: Naproxen Sodium

Anaprox DS 550mg Tablets

ACTIVE COMPARATOR

Anaprox DS 550mg Tablets of Roche Pharmaceuticals Inc

Drug: Naproxen Sodium

Interventions

Naproxen Sodium DRUG

Naproxen Sodium Tablets 550 mg

Also known as: Anaprox DS 550 mg

Anaprox DS 550mg Tablets; Naproxen Sodium 550 mg Tablets

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy human subjects within the age range of 18 to 45 years.
• Non-smokers since at least six months.
• Willingness to provide written informed consent to participate in the study.
• Body-mass index of ≥ 18.5 kg/m2 and ≤ 24.9 kg/m2, witQ body weight not less than 50 kg.
• Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening.
• Normal 12-lead ECG or one with abnormality considered to be clinically insignificant.
• Normal chest X-ray PA view.
• Comprehension of the nature and purpose of the study and compliance with the requirement of the protocol.
• Female Subjects:
• of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s) such as condoms, foams jellies, diaphragm, intrauterine device {IUD}, or abstinence or postmenopausal for at least 1 year, or surgically sterile {bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject.

You may not qualify if:

• Personal/family history of allergy or hypersensitivity to Naproxen sodium or allied drugs.
• Past history of anaphylaxis or angioedema.
• Any major illness in the past three months or any clinically significant ongoing chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.
• Presence of any clinically significant abnormal values during screening e.g significant abnormality of liver Function Test (LFT), Renal (kidney) Function Test (RFT), etc.
• Any cardiac, renal or liver impairment any other organ or system impairment.
• History of seizure or psychiatric disorders.
• Presence of disease markers of HIV 1 and 2, and hepatitis B and C virus.
• Consumption of alcohol for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study {one drink is equal to one unit of alcohol {one glass wine half pint beer, and one measure (one ounce) of spirit\].
• Consumption of xanthine containing derivatives (coffee, tea, cola drinks, chocolate) within 48 hours before check-in of each period.
• Use of any recreational drug or a history of drug addiction.
• Participation in any clinical trial within the past 3 months.
• Inaccessibility of veins in left and right arm.
• Donation of blood (one unit or 350 mL) within 3 months prior to receiving the first dose of study medication.
• Receipt of any prescription drug therapy within four weeks or over-the-counter {OTC) drugs within two weeks prior to receiving the first dose of study medication or repeated use of drugs within the last four weeks.
• An unusual diet, for whatever reason e.g. low sodium diet for two weeks prior to receiving any medication and through out subject's participation in the study.

Sponsors & Collaborators

• Dr. Reddy's Laboratories Limited: lead

Study Sites (1)

Wellquest Clinical Research

Mumbai, Maharashtra, 400 013, India

Location

MeSH Terms

Interventions

Naproxen

Intervention Hierarchy (Ancestors)

Naphthaleneacetic Acids; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds

Study Officials

• Dr. Umesh Dhakate, MBBS

  Wellquest Clinical Research

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: January 8, 2010
• First Posted: January 20, 2010
• Study Start: May 1, 2006
• Primary Completion: May 1, 2006
• Study Completion: June 1, 2006
• Last Updated: January 20, 2010

Record last verified: 2010-01

Locations

IN (1)